P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials-Reference-Cited by-同舟云学术

P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials

Published:2021-07 Issue: Volume:150 Page:47-54
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Song Pil Sang^ORCID,Park Yong Hwan,Oh Ju-Hyeon,Song Young Bin,Choi Seung-Hyuk,Gwon Hyeon-Cheol,Cho Deok-Kyu,Rha Seung-Woon^ORCID,Bae Jang-Whan,Jeong Jin-Ok,Hahn Joo-Yong

Funder

Korean Society of Cardiology

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference19 articles.

1. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease;Levine;Circulation,2016

2. 2018 ESC/EACTS Guidelines on myocardial revascularization;Neumann;Eur Heart J,2019

3. DAPT study investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents;Mauri;N Engl J Med,2014

4. Ischemic versus bleeding outcomes after percutaneous coronary interventions in patients with high bleeding risk;Gajanana;Am J Cardiol,2020

5. Meta-analysis of dual antiplatelet therapy versus monotherapy ith P2Y12 inhibitors in patients after percutaneous coronary intervention;Malik;Am J Cardiol,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology;Future Cardiology;2024-08-02

2. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial;The Lancet;2024-05

3. Prognostic Analysis and an Appropriate Antiplatelet Strategy for Patients With Percutaneous Coronary Intervention and High Bleeding Risk: Rationale and Protocol for a Multi-Center Cohort Study;Cardiology Discovery;2024-03-27

4. Aspirin-free antiplatelet strategies after percutaneous coronary interventions;European Heart Journal;2024-01-18

5. P2y12 inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials;Frontiers in Cardiovascular Medicine;2023-07-06